BPMC News and Press, Blueprint Medicines Corporation From 12/18/23

Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Dec. 18, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland , Chief Executive Officer, will pres...

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis PR Newswire -- In the European Union, patients with indolent systemic mastocytosis now have an approved medicine th...

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting PR Newswire -- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, suppo...

Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit PR Newswire CAMBRIDGE, Mass. , Nov. 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fir...

2023-11-26 07:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-15 07:00:00 ET Summary Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes. The recent uptrend in the 10-year yield, peaking around 5% in Oct...

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis PR Newswire -- For the first time, the estimated 40,000 patients with indolent SM in the EU 1,2* would have a medicine that tr...

2023-10-27 06:03:49 ET Summary Blueprint Medicines' Q3 2023 earnings showed a 90% YoY increase in product sales driven by Ayvakit, but total revenue dipped. The company has a strong financial position with $712.9M in liquid assets and an 18-month cash runway. The market respon...

2023-10-26 17:47:00 ET Shares of Blueprint Medicines (NASDAQ: BPMC) closed up 25.6% on Thursday after the cancer and blood discorder therapy company announced stronger-than-expected quarterly results. Blueprint Medicines' third-quarter revenue declined 14.1% year over year to $5...

2023-10-26 14:11:01 ET Blueprint Medicines Corporation (BPMC) Q3 2023 Earnings Conference Call October 26, 2023 08:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercia...